nvx-cov2601
Vaccineexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
2
Phase 4
0
Earliest trial started Aug 16, 2023 (NCT05973006)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
immunity, active - SARS-CoV-2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05925127 | Phase 2/Phase 3 (Phase 3) | Oct 16, 2023 | Novavax |
| NCT05973006 | Phase 3 | Aug 16, 2023 | Novavax |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novavax | For profit | 2 | 2 | 1 | 2023 |
1 organizations
Page 1 / 1